Profile data is unavailable for this security.
About the company
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
- Revenue in USD (TTM)0.00
- Net income in USD-37.34m
- Incorporated2006
- Employees16.00
- LocationSellas Life Sciences Group Inc7 TIMES SQUARE, SUITE 2503NEW YORK 10036United StatesUSA
- Phone+1 (646) 200-5278
- Fax+1 (925) 498-7799
- Websitehttps://www.sellaslifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instil Bio Inc | 0.00 | -156.09m | 69.72m | 49.00 | -- | 0.3087 | -- | -- | -24.00 | -24.00 | 0.00 | 34.72 | 0.00 | -- | -- | 0.00 | -38.65 | -- | -40.84 | -- | -- | -- | -- | -- | -- | -- | 0.265 | -- | -- | -- | 30.06 | -- | -- | -- |
| Aileron Therapeutics Inc | 0.00 | -15.73m | 70.61m | 15.00 | -- | 2.95 | -- | -- | -3.39 | -3.39 | 0.00 | 20.12 | 0.00 | -- | -- | 0.00 | -24.58 | -65.99 | -26.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| VolitionRX Ltd | 775.30k | -35.32m | 71.07m | 110.00 | -- | -- | -- | 91.67 | -0.504 | -0.504 | 0.0109 | -0.0953 | 0.0335 | -- | 4.92 | 7,048.18 | -154.29 | -111.92 | -- | -196.20 | -- | -- | -4,601.71 | -10,793.31 | -- | -280.52 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| AN2 Therapeutics Inc | 0.00 | -64.73m | 71.45m | 41.00 | -- | 0.5724 | -- | -- | -2.82 | -2.82 | 0.00 | 4.19 | 0.00 | -- | -- | 0.00 | -53.65 | -- | -58.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Rallybio Corp | 0.00 | -74.56m | 71.84m | 43.00 | -- | 0.6769 | -- | -- | -1.84 | -1.84 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -50.37 | -- | -54.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Precision BioSciences Inc | 48.73m | -42.53m | 72.48m | 109.00 | -- | 2.31 | -- | 1.49 | -10.96 | -15.86 | 12.68 | 4.53 | 0.2449 | -- | 60.12 | 447,036.70 | -21.37 | -35.35 | -29.50 | -44.22 | -- | -- | -87.28 | -147.50 | -- | -- | 0.543 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| Assembly Biosciences Inc | 7.16m | -61.23m | 72.76m | 65.00 | -- | 1.77 | -- | 10.16 | -14.02 | -14.02 | 1.63 | 7.50 | 0.06 | -- | 14.51 | 110,200.00 | -51.32 | -39.69 | -66.88 | -44.03 | -- | -- | -854.78 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| MDxHealth SA - ADR | -100.00bn | -100.00bn | 72.86m | 258.00 | -- | 10.11 | -- | -- | -- | -- | -- | 0.2641 | -- | -- | -- | -- | -- | -51.62 | -- | -64.72 | -- | 50.90 | -- | -117.64 | 1.81 | -- | 0.8513 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -37.34m | 73.93m | 16.00 | -- | -- | -- | -- | -1.37 | -1.37 | 0.00 | -0.2482 | 0.00 | -- | -- | 0.00 | -274.94 | -111.48 | -- | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | -- | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Bakhu Holdings Corp | 0.00 | -1.92m | 75.33m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -31.05m | 76.65m | 43.00 | -- | 5.61 | -- | -- | -0.6825 | -0.6825 | 0.00 | 0.2529 | 0.00 | -- | -- | -- | -84.76 | -70.19 | -97.55 | -78.31 | -- | -- | -- | -15,434.15 | 0.7822 | -42.08 | 0.4717 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -10.49m | 76.76m | 2.00 | -- | 11.83 | -- | -- | -0.4087 | -0.4087 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -86.04 | -- | -95.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Alpha Teknova Inc | 36.68m | -36.78m | 77.97m | 210.00 | -- | 0.8654 | -- | 2.13 | -1.17 | -1.17 | 1.15 | 2.21 | 0.2612 | 2.21 | 8.94 | 174,685.70 | -26.19 | -- | -28.17 | -- | 28.07 | -- | -100.26 | -- | 3.84 | -37.45 | 0.1283 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -25.79m | 78.08m | 25.00 | -- | 2.56 | -- | -- | -0.8564 | -0.8564 | 0.00 | 0.7609 | 0.00 | -- | -- | 0.00 | -60.26 | -- | -76.27 | -- | -- | -- | -- | -- | -- | -1,878.67 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| LAVA Therapeutics NV | 6.77m | -41.97m | 78.08m | 37.00 | -- | 1.53 | -- | 11.53 | -1.58 | -1.58 | 0.2532 | 1.95 | 0.0552 | -- | 2.87 | 182,946.00 | -34.25 | -- | -40.31 | -- | 48.56 | -- | -620.09 | -- | -- | -- | 0.1098 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Sellas Life Sciences Group Inc's reporting currency: US Dollar USD
5.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.14m | 2.03% |
| Armistice Capital LLCas of 31 Dec 2023 | 820.00k | 1.46% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 274.55k | 0.49% |
| Geode Capital Management LLCas of 31 Dec 2023 | 245.60k | 0.44% |
| Opus Capital Group LLCas of 31 Mar 2024 | 200.60k | 0.36% |
| Group One Trading LPas of 31 Dec 2023 | 186.36k | 0.33% |
| Equitable Advisors LLCas of 31 Dec 2023 | 165.00k | 0.29% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 97.13k | 0.17% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 62.44k | 0.11% |
| Virtu Americas LLCas of 31 Dec 2023 | 59.91k | 0.11% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
